ノースカロライナにおけるループスの臨床試験
ノースカロライナ内の拠点で、ループスに関する20件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50238, Charlotte
被験者募集中第3相
16歳以上 · 全性別 · 2026/10/02更新 · NCT06617325A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- DJL Clinical Research, PLLC, Charlotte
- Cross Creek Medical Clinic, PA, Fayetteville
被験者募集中第2相
18歳〜74歳 · 全性別 · 2026/10/01更新 · NCT07409181An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Durham
被験者募集中第3相
5歳〜17歳 · 全性別 · 2026/09/30更新 · NCT05835310A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Joint and Muscle Research Institute, Charlotte
- DJL Clinical Research, PLLC, Charlotte
- Cross Creek Medical Clinic, Fayetteville
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07438496A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Research Site, Chapel Hill
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/09/15更新 · NCT06916806A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Arthritis and Osteoporosis Consultants of the Carolinas II, LLC, Charlotte
- Superior Clinical Research, LLC, Smithfield
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT07355218A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
- Cross Creek Medical Clinic, Fayetteville
被験者募集中第2相
12歳〜70歳 · 全性別 · 2026/09/14更新 · NCT07570862A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Research Site, Chapel Hill
- Research Site, Charlotte
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/09/10更新 · NCT06897930A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Atrium Health Rheumatology-Southpark, Charlotte
- Duke University Medical Center, Durham
被験者募集中第1相
18歳〜74歳 · 全性別 · 2026/09/10更新 · NCT07085104A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- DJL Clinical Research, PLLC, Charlotte
被験者募集中観察研究
16歳以上 · 全性別 · 2026/09/03更新 · NCT07175285Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
- Research Site, Wilmington
被験者募集中観察研究
全年齢 · 女性 · 2026/09/02更新 · NCT06659029A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- University of North Carolina TraCS Institute - CTRC, Chapel Hill
被験者募集中第1相
18歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- UNC Chapel Hill, Chapel Hill
被験者募集中第1/2相
18歳〜65歳 · 全性別 · 2026/08/26更新 · NCT06121297Intervention to Improve Communication and Medication Adherence in Lupus
- Duke University, Durham
被験者募集中
18歳〜90歳 · 全性別 · 2026/08/17更新 · NCT06458075A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Duke University, Durham
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/14更新 · NCT07115745A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Duke University Health System, Durham
被験者募集中第1相
12歳〜70歳 · 全性別 · 2026/05/22更新 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- UNC Chapel Hill, Chapel Hill
被験者募集中観察研究
18歳〜110歳 · 全性別 · 2026/04/15更新 · NCT05934149Duke Lupus Registry
- Duke University Medical Center, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/01/08更新 · NCT00512694Maternal Autoimmune Disease Research Alliance (MADRA) Registry
- Duke University, Durham
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 女性 · 2026/01/08更新 · NCT03276923ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。